1. Home
  2. VOXR vs CCCC Comparison

VOXR vs CCCC Comparison

Compare VOXR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vox Royalty Corp.

VOXR

Vox Royalty Corp.

HOLD

Current Price

$5.60

Market Cap

355.5M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

N/A

Current Price

$3.41

Market Cap

404.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VOXR
CCCC
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
355.5M
404.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
VOXR
CCCC
Price
$5.60
$3.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$6.90
$12.20
AVG Volume (30 Days)
407.2K
2.0M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
1.01%
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
$60.51
N/A
Revenue Next Year
$44.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$3.44
$1.69
52 Week High
$6.70
$5.17

Technical Indicators

Market Signals
Indicator
VOXR
CCCC
Relative Strength Index (RSI) 56.50 37.89
Support Level $4.81 $3.40
Resistance Level $5.86 $3.91
Average True Range (ATR) 0.20 0.19
MACD -0.02 -0.06
Stochastic Oscillator 50.00 12.12

Price Performance

Historical Comparison
VOXR
CCCC

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty and streaming company. It holds a diversified portfolio of several royalties and streams, including producing and development stage assets, with primary exposure to gold and select industrial metals across top-tier mining jurisdictions. Vox is organized into two operating segments, consisting of acquiring and managing royalty interests; and acquiring and managing streams and other interests. Maximum revenue is generated from its Royalty Interests segment. The majority of the company's portfolio of royalty, streams, and other interests by asset count is located in Australia, Canada, and the United States, of which the maximum revenue is derived from its assets in Australia.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: